Core Insights - Dongyang Sunshine Pharmaceutical has established a dedicated liver disease team to accelerate the commercialization of innovative hepatitis C drugs [2][3] - The company has received approval for two hepatitis C drugs, Dongweizhuo and Dongyinghe, which are designed for the treatment of chronic hepatitis C virus infections [2][3] - The company is working to reduce its reliance on its flu drug Oseltamivir, which has seen a decline in sales contribution from 81.2% in 2022 to an expected 64.2% in 2024 [2][3] Company Developments - The newly formed liver disease team operates across seven major business areas, including Shanghai, Guangzhou, and Beijing, with a total workforce of over 100 [3] - Dongyang Sunshine Pharmaceutical has three liver disease drugs approved for market, addressing a significant public health issue in China where approximately 10 million people are infected with hepatitis C [3] - The company is attempting to push its hepatitis C drugs into the new round of national medical insurance catalog [4] Market Context - The market for hepatitis C treatments is competitive, with 17 direct-acting antiviral drugs (DAAs) approved in China, eight of which are included in the national medical insurance directory [3] - Dongyang Sunshine Pharmaceutical's ability to succeed in the hepatitis C market will depend on its commercialization capabilities [3]

Core Viewpoint - Dongyangguang Pharmaceutical is restructuring its sales team to focus on liver disease, aiming to accelerate the commercialization of innovative hepatitis C drugs [3][5]. Group 1: Company Developments - In August, Dongyangguang Pharmaceutical established a dedicated liver disease team to enhance the commercialization of its hepatitis C treatments [3]. - The company has received approval for two innovative hepatitis C drugs, Dongweizhuo (Nafamostat) and Dongyinghe (Echocardiography), which can treat chronic hepatitis C virus infections in adults [3][4]. - The sales of the flu drug Oseltamivir, known as Kewai, have decreased from 81.2% of total sales in 2022 to 64.2% in 2024, indicating a shift in the company's revenue reliance [3]. Group 2: Market Context - There are approximately 10 million hepatitis C patients in China, but the diagnosis and treatment rates are low, presenting a significant public health challenge [5]. - Dongyangguang Pharmaceutical's new hepatitis C drugs provide additional treatment options for patients, but the company faces competition from other manufacturers in the hepatitis C drug market [5]. - Currently, there are 17 approved direct-acting antiviral drugs (DAA) for chronic hepatitis C in China, with eight included in the national medical insurance catalog [5].